Researchers from the Urban Institute find UnitedHealth's statements about leaving the exchanges at odds with recent actions.
The head of the largest state-run exchange wants UnitedHealth to stop blaming its losses on the Affordable Care Act and instead look at its own actions, according to California Healthline, which reported the interview with Peter Lee, executive director of Covered California.
Since November, UnitedHealth has made a series of statements to explain its losses on both state and federal exchanges in 2015. UnitedHealth sat out the launch of Obamacare in 2014, but will join the California market for 2016. Mistakes in pricing and networks led to losses of $475 million on the exchanges for 2015, and the projection for this year is $500 million.
While UnitedHealth blames the construction of the ACA exchanges and elements of the law, Lee told the news outlet that the insurer has only itself to blame. "Instead of saying, 'We screwed up,' they said, 'Obamacare is the problem and we may not play anymore,'" he said, referencing UnitedHealth’s statements that it may bolt the exchanges for 2017.
“It was giving an excuse to Wall Street and throwing the Affordable Care Act under the bus,” Lee said.
A report from Urban Institute last week found that a little of each is true. Researchers there agree with insurers like UnitedHealth and Aetna that special enrollment provisions are being abused and need to be tightened up so that consumers don’t wait until they are sick to seek coverage. Under the law, consumers can use special enrollment to make changes for life events such as moving, getting married or having a child.
A core element of the ACA is the individual mandate, which requires each person to have coverage or pay a penalty, which this year rose to a $695 or 2.5% of income. Insurers need enough healthy adults to sign up for coverage to offset payments for those who are sick and use insurance frequently.
The Urban Institute did find, however, that UnitedHealth tended to charge more than its competitors and had larger provider networks, which attracted sicker enrollees who needed hard-to-find specialists. UnitedHealth often found its way to smaller markets with limited competition, so if it leaves the exchanges in 2017, its former competitors could feel free to raise premiums, the report found.
Some feel UnitedHealth erred with its slow entry into many markets, including a decision to wait 2 full years to join the California market. Now, the insurer faces a steep learning curve against competitors who have 2 years’ worth of experience and claims data to use in pricing their products.
The Urban Institute said UnitedHealth’s statements are at odds with recent events.
“Our basic conclusion is that marketplaces are increasingly driven by competition among Blue Cross—affiliated insurers, Medicaid insurers, provider-sponsored insurers, and in fewer regions, local or regional insurers,” the authors wrote.
“In addition, given that United is expanding into more marketplaces in 2016 and their participation is growing significantly this year after even larger relative growth in 2015, their discussion to pull out of the marketplaces is surprising.”
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More